$0.33 EPS Expected for Natus Medical Inc (BABY)

July 18, 2017 - By Adrian Mccoy

 $0.33 EPS Expected for Natus Medical Inc (BABY)
Investors sentiment increased to 1.93 in 2016 Q4. Its up 0.82, from 1.11 in 2016Q3. It increased, as 11 investors sold Natus Medical Inc shares while 56 reduced holdings. 51 funds opened positions while 78 raised stakes. 29.10 million shares or 6.34% more from 27.36 million shares in 2016Q3 were reported.
Etrade Capital Mngmt Ltd Liability Co stated it has 0.05% of its portfolio in Natus Medical Inc (NASDAQ:BABY). Systematic L P invested in 0.02% or 42,739 shares. Blackrock Fund Advisors owns 0.02% invested in Natus Medical Inc (NASDAQ:BABY) for 2.69M shares. Blackrock Institutional Com Na reported 855,371 shares stake. Clinton invested in 11,352 shares. Credit Suisse Ag holds 0% or 68,247 shares in its portfolio. State Board Of Administration Of Florida Retirement System owns 25,390 shares. Columbia Wanger Asset Limited Liability Co holds 0.29% in Natus Medical Inc (NASDAQ:BABY) or 590,825 shares. Rice Hall James Assoc Lc reported 474,316 shares. Quantbot Tech Lp owns 0.03% invested in Natus Medical Inc (NASDAQ:BABY) for 7,186 shares. Eventide Asset Management Ltd Llc owns 0.17% invested in Natus Medical Inc (NASDAQ:BABY) for 75,000 shares. Los Angeles Cap Management And Equity Research Incorporated invested in 0.01% or 32,899 shares. Alphamark Advsrs Ltd Llc has 0.42% invested in Natus Medical Inc (NASDAQ:BABY) for 23,320 shares. Blackrock Incorporated has invested 0% of its portfolio in Natus Medical Inc (NASDAQ:BABY). Moreover, Cap Fund Mgmt Sa has 0.01% invested in Natus Medical Inc (NASDAQ:BABY).

Since February 9, 2017, it had 2 buys, and 3 insider sales for $190,940 activity. GUNST ROBERT A also sold $180,000 worth of Natus Medical Inc (NASDAQ:BABY) shares. HAWKINS JAMES B bought $202,860 worth of stock. 5,000 shares were sold by Engibous Doris, worth $163,400 on Thursday, May 25. $186,300 worth of Natus Medical Inc (NASDAQ:BABY) shares were sold by MOORE WILLIAM M.

Analysts expect Natus Medical Inc (NASDAQ:BABY) to report $0.33 EPS on July, 19.They anticipate $0.06 EPS change or 15.38 % from last quarter’s $0.39 EPS. BABY’s profit would be $11.17 million giving it 28.64 P/E if the $0.33 EPS is correct. After having $0.30 EPS previously, Natus Medical Inc’s analysts see 10.00 % EPS growth. The stock increased 1.34% or $0.5 during the last trading session, reaching $37.8. About shares traded. Natus Medical Inc (NASDAQ:BABY) has risen 4.38% since July 18, 2016 and is uptrending. It has underperformed by 12.32% the S&P500.

Natus Medical Inc (NASDAQ:BABY) Ratings Coverage

Among 4 analysts covering Natus Medical (NASDAQ:BABY), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Natus Medical has $55 highest and $39 lowest target. $48.67’s average target is 28.76% above currents $37.8 stock price. Natus Medical had 8 analyst reports since July 23, 2015 according to SRatingsIntel. On Thursday, February 2 the stock rating was downgraded by Raymond James to “Mkt Perform”. The company was maintained on Thursday, October 22 by TH Capital. Roth Capital maintained Natus Medical Inc (NASDAQ:BABY) rating on Tuesday, April 5. Roth Capital has “Buy” rating and $39 target. The firm earned “Buy” rating on Friday, June 23 by Roth Capital. The company was upgraded on Tuesday, September 13 by Raymond James. The rating was initiated by Benchmark on Tuesday, October 4 with “Buy”. TH Capital maintained Natus Medical Inc (NASDAQ:BABY) on Tuesday, January 12 with “Buy” rating. The stock has “Buy” rating by TH Capital on Thursday, July 23.

Natus Medical Incorporated is a provider of newborn care and neurology healthcare services and products used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The company has market cap of $1.28 billion. The Company’s product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories. It has a 34.8 P/E ratio.

More notable recent Natus Medical Inc (NASDAQ:BABY) news were published by: Fool.com which released: “Natus Medical Inc: This BABY Has Some Growing Pains” on April 27, 2017, also Fool.com with their article: “Natus Medical Inc Hears a Bright 2017” published on February 02, 2017, Fool.com published: “Natus Medical Inc.: This BABY Keeps Chugging Along” on October 20, 2016. More interesting news about Natus Medical Inc (NASDAQ:BABY) were released by: Fool.com and their article: “Why Natus Medical Inc. Sank Today” published on April 26, 2017 as well as Fool.com‘s news article titled: “Natus Medical Inc. Fell 11% in April. Here’s Why.” with publication date: May 08, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.